Metabiota raises $30 Million

What does Metabiota do?

Metabiota,  is a pioneer in comprehensive risk analytics which improves the world’s resilience to epidemics. It leverages science, health and data analytics for gaining actionable insights into human and animal health. It is built on a strong foundation international field science and epidemiology, which includes a worldwide network of on the ground experts.

This startup delivers actionable insights which are data driven to help governments, countries and corporation for managing and mitigating infectious diseases. With a sustained partnerships and strategic presence around the globe and its agile approach is helping the world in tracking, transferring and terminating the risk which is associated with epidemic threats. It operates in 20 countries and has offices in China, Canada, San Fransico, Washington, Sierra Leone and Ukraine.

How much Metabiota was funded?

Metabiota raised $30 M in Series A funding from SharesPost Investment Management, James Joaquin, Undercurrent,Steven Luczo, HVF and Data Collective and other angel investors.

Previous funding

$2.8M in Seed funding March 20, 2014 from RSTP, Tao Capital Partners, HVF, Adrian Aoun, Tim O’Reilly and James Joaquin.

What is next for Metabiota?

Metabiota  has raised a total of $32.8M to date. The company plans to use the latest funding to help build its offerings to insurers and government organizations on a global scale. The company considers this round of funding more of a growth round. The funds will used for scaling its business and continue building into more areas all over the world. The funds will also be used to hire engineers and working with the insurers and reinsurers for providing financial tools to government for the epidemic outbreaks.

More about Metabiota

Metabiota was founded in 2008 by Nathan Wolfe. It has its headquarters in San Francisco. It uses computer modeling for predicting and preventing outbreaks in populations over the globe, including Asia and Africa. It is digitizing the world’s microbial threats so that insurance companies, governments etc can fight disease spread and epidemic risk financing.